Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Key Highlights
- ➤Fortrea and Omico announce collaboration to accelerate biomarker-driven oncology trials
- ➤Omico database includes more than 23,000 consented patients across Australia
- ➤Omico has received referrals from more than 1,600 clinicians nationwide
- ➤PrOSPeCT provides molecular profiling and matches patients with targeted trials
- ➤Collaboration aims to improve trial planning, site selection and patient recruitment
Expert Statements
Oren Cohen, Chief Medical Officer at Fortrea
“Our collaboration with Omico is about seeking to reach the right patient for the right study as quickly as possible”
Oren Cohen, Chief Medical Officer at Fortrea
“Modern oncology development demands ever-greater precision to match specific cancers with the therapies most likely to benefit patients, and to do so as quickly as possible.”
Oren Cohen, Chief Medical Officer at Fortrea
“Our work with Omico accelerates our ability to identify the right patients for biomarker-driven studies in Australia and help advance precision medicine for people with cancer.”
David Thomas, Chief Science and Strategy Officer at Omico
“Australia is well positioned to support global biomarker-driven clinical trials, through Omico’s established national precision oncology research infrastructure, expertise and networks”
David Thomas, Chief Science and Strategy Officer at Omico
“By combining our national data and trial matching capabilities with Fortrea’s global clinical development expertise, we can help international sponsors identify relevant patient populations, plan trials more effectively and support targeted recruitment.”
Highlights * Collaboration aims to accelerate precision oncology research in Australia * Combines Fortrea’s experience in oncology clinical trials with Omico’s Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program * Together, Fortrea and Omico offer more efficient investigator site selection and faster patient access by connecting patients with relevant biomarker-driven clinical trials DURHAM, N.C. and SYDNEY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), and Omico, Australia’s leading precision oncology screening and trial matching organization, today announced a collaboration to accelerate precision oncology research by helping connect cancer patients to biomarker-matched clinical trials. By combining Omico's precision oncology network with Fortrea's scientific and clinical trial experience, the joint effort aims to improve study planning, site selection and patient recruitment to expand access to biomarker-driven oncology research globally.
Get started
Create a free account to read the full story.